跳至主要内容
临床试验/NCT01825317
NCT01825317已完成不适用

Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients

Neuronix Ltd1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2013年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Neuronix Ltd
入组人数
32
试验地点
1
主要终点
ADAS-Cog

研究概览

简要总结

Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.

详细描述

Synchronized TMS and cognitive training for the treatment of mild to moderate Alzheimer's patients. Treatment is delivered 5 days a week, for 6 weeks, visit is about an hour long.

Evaluation is by neuropsychological evaluation at 6 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female age 60-90 years
  • Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSM-IV criteria.
  • MMSE score 18 to 26
  • Adas-cog above 17
  • Physically acceptable for the study as confirmed by medical history and exam.
  • Spouse, family member or professional caregiver agree and capable of taking care and be responsible for the participation of the patient in the study (answering questions regarding the patient's condition and assuming responsibility for medication)
  • Agreement to participate in approximately 14 weeks during the study.
  • Normal or corrected to normal ability to see and to hear.
  • Korean as primary language
  • 8th grade education minimum

排除标准

  • Severe agitation;
  • Mental retardation;
  • Patient lacking capacity to consent to study participation
  • Unstable medical condition;
  • Use of benzodiazepines or barbiturates during the study and preceding two weeks;
  • Pharmacological immunosuppression;
  • Participation in a clinical trial with any investigational agent within two weeks prior to study enrollment;
  • History of Epileptic Seizures or Epilepsy;
  • Contraindication for performing MRI scanning;
  • Contraindication for receiving TMS treatment according to a TMS questionnaire;
  • Pregnant women, and women who have the ability to become pregnant unless they are on an acceptable method of contraception during the study.
  • Patients with personal history of any clinically defined neurological disorder, including organic brain disease, epilepsy, stroke, brain lesions, or multiple sclerosis; or personal history of previous neurosurgery or head trauma that resulted in loss of consciousness.
  • Patients with depression, bipolar disorder or psychotic disorders or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
  • Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
  • Patients treated with cholinesterase inhibitors, or memantine or Ginko-biloba will be allowed to participate, if the treatment has started at least 6 months previous to recruitment. The patients should keep their dose of medication during the whole trial as prior to study begin.
  • Patients with metal in the head, except the mouth (i.e. cochlear implants, implanted brain stimulators, aneurysm clips)
  • Patients with increased intracranial pressure
  • Cardiac pacemakers
  • Implanted neurostimulators
  • Implanted medication pumps
  • Intracardiac lines
  • Significant heart disease
  • Currently taking medication that lower the seizure threshold
  • Significant sleep deprivation and alcoholism

结局指标

主要结局

ADAS-Cog

时间窗: 6 weeks

Alzheimer's disease assessment scale - cognitive test

次要结局

未报告次要终点

研究者

发起方
Neuronix Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验